Corcept Therapeutics (CORT) Tops Q3 EPS by 13c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 --0%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
XFOR, MG, YORW, More
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
XFOR, MG, YORW, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.41, $0.13 better than the analyst estimate of $0.28. Revenue for the quarter came in at $182.5 million versus the consensus estimate of $171.98 million.
GUIDANCE:
Corcept Therapeutics sees FY2024 revenue of $675-700 million, versus the consensus of $661.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- Air Products (APD) Reports In-Line Q4 EPS ; Offers Guidance
- Lemonade (LMND) Tops Q3 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
